Lexicon Pharmaceuticals Inc Receives Formal Dispute Resolution Request Decision From FDA's Office of New Drugs For Sotagliflozin In Type 1 Diabetes - Call Transcript
Hello, and welcome to the Lexicon Pharmaceuticals Sotagliflozin Type 1 Diabetes Update. (Operator Instructions) As a reminder, this call is being recorded today, December 2, 2019.
I will now turn the call over to Dr. Kimberly Lee,ac Head of Investor Relations and Corporate Strategy. Please go ahead.
Thank you, Carmen, and good morning and welcome to the Lexicon Pharmaceuticals Sotagliflozin Type 1 Diabetes Update Conference Call. Joining me on today's call are Lonnel Coats, Lexicon's President and Chief Executive Officer; Alex Santini, Executive Vice President and Chief Commercial Officer; Dr. Pablo Lapuerta, Executive Vice President and Chief Medical Officer; Dr. Praveen Tyle, Executive Vice President of Research and Development; and Jeff Wade, Executive Vice President of Corporate and Administrative Affairs and Chief Financial Officer.
After our formal remarks, we will open the call up for Q&A.
Earlier today, Lexicon issued a press release
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
